150 related articles for article (PubMed ID: 37706094)
1. Discontinuation of infliximab treatment in patients with inflammatory bowel disease who retransitioned to originator and those who remained on biosimilar.
Meijboom RW; Gardarsdottir H; Becker ML; Movig KLL; Kuijvenhoven J; Egberts TCG; Giezen TJ
Therap Adv Gastroenterol; 2023; 16():17562848231197923. PubMed ID: 37706094
[TBL] [Abstract][Full Text] [Related]
2. Patients Retransitioning from Biosimilar TNFα Inhibitor to the Corresponding Originator After Initial Transitioning to the Biosimilar: A Systematic Review.
Meijboom RW; Gardarsdottir H; Egberts TCG; Giezen TJ
BioDrugs; 2022 Jan; 36(1):27-39. PubMed ID: 34870802
[TBL] [Abstract][Full Text] [Related]
3. Incidence of and Reasons and Determinants Associated with Retransitioning from Biosimilar Etanercept to Originator Etanercept.
Meijboom RW; Gardarsdottir H; Becker ML; Ten Wolde S; Egberts TCG; Giezen TJ
BioDrugs; 2021 Nov; 35(6):765-772. PubMed ID: 34704199
[TBL] [Abstract][Full Text] [Related]
4. Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab: a multicentre, parallel cohort study.
Haifer C; Srinivasan A; An YK; Picardo S; van Langenberg D; Menon S; Begun J; Ghaly S; Thin L
Med J Aust; 2021 Feb; 214(3):128-133. PubMed ID: 33070332
[TBL] [Abstract][Full Text] [Related]
5. Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab.
Fitzgerald T; Melsheimer R; Lafeuille MH; Lefebvre P; Morrison L; Woodruff K; Lin I; Emond B
Biologics; 2021; 15():1-15. PubMed ID: 33442230
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of biosimilar versus originator infliximab in patients with inflammatory bowel disease: A real-world cohort analysis.
Kumar P; Vuyyuru SK; Kante B; Kedia S; Sahu P; Ranjan MK; Mundhra S; Golla R; Kumar M; Virmani S; Gupta A; Yadav N; Makharia G; Ahuja V
Indian J Gastroenterol; 2022 Oct; 41(5):446-455. PubMed ID: 36378484
[TBL] [Abstract][Full Text] [Related]
7. Switching Between Infliximab Originator and Biosimilar in Paediatric Patients with Inflammatory Bowel Disease. Preliminary Observations.
Sieczkowska J; Jarzębicka D; Banaszkiewicz A; Plocek A; Gawronska A; Toporowska-Kowalska E; Oracz G; Meglicka M; Kierkus J
J Crohns Colitis; 2016 Feb; 10(2):127-32. PubMed ID: 26721942
[TBL] [Abstract][Full Text] [Related]
8. Switching from originator infliximab to biosimilar versus continuing on originator in inflammatory bowel disease: results from the observational Project NORTH study.
Hellström PM; Gemmen E; Ward HA; Koo H; Faccin F; Xue Z; Malmborg P
Scand J Gastroenterol; 2022 Dec; 57(12):1435-1442. PubMed ID: 35833832
[TBL] [Abstract][Full Text] [Related]
9. Real-world outcomes of switching from adalimumab originator to adalimumab biosimilar in patients with inflammatory bowel disease: The ADA-SWITCH study.
Casanova MJ; Nantes Ó; Varela P; Vela-González M; Rivero M; Sierra-Gabarda O; Riestra S; Barreiro-de Acosta M; Martín-Rodríguez MDM; Gargallo-Puyuelo CJ; Reygosa C; Muñoz R; de la Filia-Molina IG; Núñez-Ortiz A; Kolle L; Calafat M; Huguet JM; Iglesias-Flores E; Martínez-Pérez TJ; Bosch O; Duque-Alcorta JM; Frago-Larramona S; Van Domselaar M; González-Cosano VM; Bujanda L; Rubio S; Mancebo A; Castro B; García-López S; de Francisco R; Nieto-García L; Laredo V; Gutiérrez-Casbas A; Mesonero F; Leo-Carnerero E; Cañete F; Ruiz L; Gros B; Del Moral-Martínez M; Rodríguez C; Chaparro M; Gisbert JP
Aliment Pharmacol Ther; 2023 Jul; 58(1):60-70. PubMed ID: 37089065
[TBL] [Abstract][Full Text] [Related]
10. Long-term effectiveness and pharmacokinetics of the infliximab biosimilar CT-P13 after switching from the originator during the treatment of inflammatory bowel disease.
Martín-Gutiérrez N; Sánchez-Hernández JG; Rebollo N; Pordomingo AF; Muñoz F; Otero MJ
Eur J Hosp Pharm; 2022 Jul; 29(4):222-227. PubMed ID: 33115797
[TBL] [Abstract][Full Text] [Related]
11. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial.
Strik AS; van de Vrie W; Bloemsaat-Minekus JPJ; Nurmohamed M; Bossuyt PJJ; Bodelier A; Rispens T; van Megen YJB; D'Haens GR;
Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):404-412. PubMed ID: 29606564
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience.
Ratnakumaran R; To N; Gracie DJ; Selinger CP; O'Connor A; Clark T; Carey N; Leigh K; Bourner L; Ford AC; Hamlin PJ
Scand J Gastroenterol; 2018 Jun; 53(6):700-707. PubMed ID: 29687730
[TBL] [Abstract][Full Text] [Related]
13. Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry.
Nabi H; Hendricks O; Jensen DV; Loft AG; Pedersen JK; Just SA; Danebod K; Munk HL; Kristensen S; Manilo N; Colic A; Linauskas A; Thygesen PH; Christensen LB; Kalisz MH; Lomborg N; Chrysidis S; Raun JL; Andersen M; Mehnert F; Krogh NS; Hetland ML; Glintborg B
RMD Open; 2022 Nov; 8(2):. PubMed ID: 36418087
[TBL] [Abstract][Full Text] [Related]
14. Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral Center.
Bronswijk M; Moens A; Lenfant M; Tops S; Compernolle G; Van Assche G; Vermeire S; Gils A; Ferrante M
Inflamm Bowel Dis; 2020 Mar; 26(4):628-634. PubMed ID: 31400283
[TBL] [Abstract][Full Text] [Related]
15. Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab.
Fischer S; Cohnen S; Klenske E; Schmitt H; Vitali F; Hirschmann S; Ramming A; Zundler S; Rath T; Krebs S; Dörje F; Uter W; Nagore D; Meyer S; Neurath MF; Atreya R
Therap Adv Gastroenterol; 2021; 14():1756284820982802. PubMed ID: 33505519
[TBL] [Abstract][Full Text] [Related]
16. Infliximab concentrations in two non-switching cohorts of patients with inflammatory bowel disease: originator vs. biosimilar.
Martínez-Feito A; Bravo-Gallego LY; Hernández-Breijo B; Diez J; García-Ramirez L; Jaquotot M; Plasencia-Rodríguez C; Nozal P; Mezcua A; Martín-Arranz MD; Pascual-Salcedo D
Sci Rep; 2020 Oct; 10(1):17099. PubMed ID: 33051546
[TBL] [Abstract][Full Text] [Related]
17. Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme.
Razanskaite V; Bettey M; Downey L; Wright J; Callaghan J; Rush M; Whiteoak S; Ker S; Perry K; Underhill C; Efrem E; Ahmed I; Cummings F
J Crohns Colitis; 2017 Jun; 11(6):690-696. PubMed ID: 28130330
[TBL] [Abstract][Full Text] [Related]
18. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial.
Jørgensen KK; Olsen IC; Goll GL; Lorentzen M; Bolstad N; Haavardsholm EA; Lundin KEA; Mørk C; Jahnsen J; Kvien TK;
Lancet; 2017 Jun; 389(10086):2304-2316. PubMed ID: 28502609
[TBL] [Abstract][Full Text] [Related]
19. Health-related quality of life and costs of switching originator infliximab to biosimilar one in treatment of inflammatory bowel disease.
Huoponen S; Eberl A; Räsänen P; Roine RP; Sipponen T; Arkkila P; Blom M
Medicine (Baltimore); 2020 Jan; 99(2):e18723. PubMed ID: 31914087
[TBL] [Abstract][Full Text] [Related]
20. Outcomes after double switching from originator Infliximab to biosimilar CT-P13 and biosimilar SB2 in patients with inflammatory bowel disease: a 12-month prospective cohort study.
Trystram N; Abitbol V; Tannoury J; Lecomte M; Assaraf J; Malamut G; Gagnière C; Barré A; Sobhani I; Chaussade S; Amiot A
Aliment Pharmacol Ther; 2021 Apr; 53(8):887-899. PubMed ID: 33647174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]